Markets
Warren Buffett 1991
Buffett as a mere lad of 61 years, back in 1991 (Mark Reinstein/Getty Images)

Warren Buffett’s Berkshire Hathaway is at an all-time high. Is that a sign of what investors want right now?

As Berkshire Hathaway hits a peak, it could be a sign that investors are looking for some old-fashioned American certainty in their bets.

Shares of Berkshire Hathaway, the insurance-company-slash-holding-company-slash-investment-vehicle that Warren Buffett has led since 1965, closed at a record high of more than $747,000 on Monday, and is flat midday Tuesday.

The latest increase for Berkshire followed the record quarterly and annual profit the company reported Saturday. Just for funsies: Berkshire stock is up 1.08 million percent — not a typo — since September of 1976, the first trading data available through FactSet.

According to the investing principles Buffett has adhered to for the better part of a century, this is precisely how things are supposed to work. Share prices should be a reflection of the profit-producing power of actual companies. Under this ethos, known as value investing, the basic goal of investors is to try to buy stocks that are undervalued relative to the profits they should reasonably be expected to generate.

Those so-called value stocks had largely underperformed since the election, as investors have flocked to growth stocks, which carry high price-to-earnings multiples. That suggested the market was extremely excited about companies for reasons that weren’t immediately showing up in their profit estimates published by Wall Street analysts.

To be sure, Wall Street analysts aren’t always right. Sometimes, investors see things spreadsheet-wielding Wall Street wonks don’t. (For instance, Palantir, which is insanely overvalued according to traditional metrics, posted off-the-charts earnings that sent the shares sharply higher.)

We’ve argued that some of the best-performing shares of the post-election period, including Palantir and Tesla, have cozy political and financial ties to Trump world, suggesting that the market was pricing in some sort of business benefit from the new administration.

While the specific nature of such benefits are never clearly spelled out — favorable regulatory actions? Easing antitrust hurdles to mergers? Preference for juicy federal contracts? — Wall Street often has trouble incorporating murky to corrupt relationships into their analytical models.

But things seem to have shifted a bit lately.

In recent days, as the Trump administration has shown just how willing it is to break with the conventions and government behavior that have underwritten American prosperity since 1945, the market seems to have gotten a bit less sanguine about buying stocks and shares of companies with close links to Trump. (Palantir, again a case in point, has taken a beating.)

Instead, investors are looking for some good old-fashioned certainty about America in their investments. Consumer staple stocks have leapt to become the best-performing of the S&P 500’s 11 sectors, rising more than 8% this year. Hershey, Yum! Brands, Hasbro, T-Mobile, AT&T, and Oreo maker Mondelez are some of the best-performing stocks in February.

So it seems like a sign of the times that Buffett’s conglomerate — which has long-standing bets on such tried and true American staples as Coca-Cola, Kraft Heinz, and See’s Candies — has overtaken Trump agent Elon Musk’s Tesla in market value in recent days, as the market seems to be reassessing the speculative and political frenzy that has set in since November.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets
Luke Kawa

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.